Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple
(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the California-based company said on Wednesday. Deep Apple …